CoDiagnostics Secures Japanese Patent for Innovative Diagnostic Technology Advancement

CoDiagnostics Breaks Ground with Japanese Patent for Advanced Diagnostic Platform

CoDiagnostics, Inc. (Nasdaq: CODX), a leading player in the molecular diagnostics sector, receives a significant boost with the granting of Japanese Patent No. 7797537 by the Japan Patent Office (JPO). This patent, which illustrates the company's cutting-edge technology—“Systems, Methods, and Apparatus for Automated Self-Contained Biological Analysis”—is pivotal for fortifying Co-Diagnostics' intellectual property (IP) portfolio. Registered on December 26, 2025, the patent encompasses 34 claims, enhancing the Co-Dx PCR Pro® instrument and its associated point-of-care testing solutions that aim to change the landscape of infectious disease diagnostics.

Dwight Egan, CEO of Co-Diagnostics, underscores the importance of the JPO's stringent review process, declaring it a testament to the uniqueness and innovation embedded in their technology. The granting of this patent follows a similar accomplishment in Australia earlier in 2025, reflecting the company's strategic initiatives to safeguard its innovation globally. This development is particularly crucial as Co-Diagnostics targets expansion in key international markets, helping to build a robust framework for the commercialization of its diagnostic solutions, which are designed for decentralized testing environments.

The Co-Dx PCR platform distinguishes itself with its compact, user-friendly design while maintaining gold-standard PCR accuracy. It employs patented Co-Primers® technology, offering fast and reliable molecular diagnostics across diverse applications. With its recent patent in hand, Co-Diagnostics enhances its ability to forge commercial partnerships, especially in Japan, augmenting the availability of affordable, high-performance PCR testing options. While the patent positions the company favorably, it is important to note that the Co-Dx PCR platform is still undergoing regulatory reviews and is not yet commercially available.

In addition to the patent news, Co-Diagnostics is poised to leverage its strong IP portfolio to explore new opportunities for collaboration and expansion across various healthcare sectors. As the demand for rapid and accurate testing solutions grows globally, the company's innovative offerings stand to meet a pressing need in infectious disease diagnostics. This patent milestone is an essential step in strengthening Co-Diagnostics' market position and fostering future growth within the ever-evolving molecular diagnostics industry.